logo
Mysterious Signals From Deep Space Hint at Something Brutal, Scientists Say

Mysterious Signals From Deep Space Hint at Something Brutal, Scientists Say

Yahoo3 days ago
Astronomers believe they've uncovered the source behind mysterious cosmic signals known as fast X-ray transients (FXTs) — and it adds a grim twist to our understanding of the death of stars.
Right as a massive star explodes in a supernova, it unleashes a tremendously energetic stream of particles called a jet, producing a gamma ray burst — one of the most powerful explosions in the universe. The rest of the star, typically, collapses into a black hole.
But a pair of new studies suggests that this last gasp by a star before winking out of existence can get "trapped" by some of the star's own remains, slamming the door shut on the jet so it can't fully shine.
"As the jet is being launched, that extra material from the star that didn't collapse into the black hole [interacts] with the jet in such a way that sort of suppresses the jet from actually breaking out of the outer layers," Jillian Rastinejad, an astronomer at Northwestern University and lead author of one the two studies set to published in the The Astrophysical Journal Letters, told Gizmodo.
That produces the weaker X-ray emissions, in the form of an FXT, which can last from seconds to hours.
The nickname astronomers have for these weakened blasts is nearly as brutal as the catastrophic event itself: a "failed" jet.
According to the findings, FXTs arise from a type of stellar explosion called a Type Ic supernova, which occurs in stars that have long shed their outermost layers of hydrogen and helium.
Because of their ephemeral nature and the extreme distance of most detected FXTs to date, pinpointing their origins has been a challenge for astronomers.
Rastinejad and her team's breakthrough came when data collected in the Einstein Probe, an X-ray telescope program run by the Chinese Academy of Sciences in collaboration with the European Space Agency, revealed an FXT that was unusually close to Earth — a mere 2.8 billion light years away.
Dubbed EP 250108a, telescopes including the Keck Observatory in Hawai'i and the James Webb Space Telescope rushed to extensively image the X-ray burst in multiple wavelengths, collecting infrared and optical data.
"It's important to note that X-ray data alone cannot tell us what phenomena created an FXT," Rastinejad said in a statement about the work. "Rapid observations of the location of the FXT at optical and infrared wavelengths are key to identifying the aftermath of an FXT and assembling clues to its origin."
With that wealth of data, the astronomers were able to observe how the signal evolved over time. Over the course of several weeks, the stunted supernova increased in brightness before eventually fading. The brief peak in brightness allowed the astronomers to determine that the blast was a Type Ic supernova — and one that was clearly lacking a gamma ray burst.
This has profound implications for our understanding of a star's demise, because according to the work, with sufficiently large stars — the one that produced EP 250108a is estimated to be between 15 to 30 times heavier than the Sun — the full-blown gamma ray bursts we've come to equate with supernovas may not actually be the norm.
Instead, Rastinejad said, "this 'trapped' jet outcome is more common in massive star explosions than jets that successfully emerge from the star."
More on space: Astronomers Capture First-Ever Image of Star That Exploded Twice
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

See it: Closest image of Sun yet taken by NASA's Parker Solar Probe
See it: Closest image of Sun yet taken by NASA's Parker Solar Probe

Yahoo

time30 minutes ago

  • Yahoo

See it: Closest image of Sun yet taken by NASA's Parker Solar Probe

Last year, NASA's Parker Solar Probe made its record-breaking flyby of the Sun, zooming just 3.8 million miles from the solar surface, and we're just now seeing some results from that close brush with our star. This week, Nasa released new images taken by the spacecraft from the record-breaking close approach of the Sun, including from an instrument called WISPER. As Parker skimmed through the Sun's outer atmosphere, known as the corona, it used the Wide-Field Imager for Solar Probe (WISPR) to observe the corona and solar wind. Nasa's Parker Solar Probe Makes Historic Christmas Eve Flight Through Sun's Atmosphere The video below was created with images from WISPR, which shows solar wind in never-before-seen detail. According to NASA, this close-up shows what happens right after solar wind comes blasting out from the corona. It also shows multiple collisions of coronal mass ejections, or CMEs, the space weather phenomena most known for creating aurora lights on Earth. This data could be key to understanding space weather, according to Angelos Vourlidas, the WISPR instrument scientist with Johns Hopkins Applied Physics Laboratory in Maryland. NASA said as CMEs collide, their trajectory can change, making space weather forecasting more difficult to predict if these charged particles are headed for Earth. Still, scientists do not know how solar wind is created. "The big unknown has been: how is the solar wind generated, and how does it manage to escape the Sun's immense gravitational pull?" said Nour Rawafi, the project scientist for Parker Solar Probe at the Johns Hopkins Applied Physics Laboratory. "Understanding this continuous flow of particles, particularly the slow solar wind, is a major challenge, especially given the diversity in the properties of these streams — but with Parker Solar Probe, we're closer than ever to uncovering their origins and how they evolve." Parker Solar Probe was named after the heliophysist Eugene Parker, who first theorized this concept in 1958. Parker was at the launch of the spacecraft with his namesake in 2018. He passed away at 94-years-old in 2022. article source: See it: Closest image of Sun yet taken by NASA's Parker Solar Probe

PHASE Scientific Expands INDICAID® Respiratory Portfolio with Exclusive U.S. Launch of Novel FebriDx® Test
PHASE Scientific Expands INDICAID® Respiratory Portfolio with Exclusive U.S. Launch of Novel FebriDx® Test

Yahoo

timean hour ago

  • Yahoo

PHASE Scientific Expands INDICAID® Respiratory Portfolio with Exclusive U.S. Launch of Novel FebriDx® Test

FebriDx® is a first-in-class rapid test that differentiates between bacterial and non-bacterial respiratory infections, offering significant potential to address critical unmet needs in patient care by enabling more informed antibiotic use and aiding in the reduction of antimicrobial resistance. Introduction of FebriDx will enhance PHASE Scientific's INDICAID® portfolio and strengthen its leadership in point-of-care respiratory diagnostics. Partnership underscores PHASE Scientific's proven commercial execution in the U.S. market with its extensive nationwide clinical network, building upon its strengths in R&D innovation. GARDEN GROVE, Calif., July 15, 2025 /PRNewswire/ -- PHASE Scientific, a fast-growing biotech company known for its science-driven innovation and commitment to improving healthcare outcomes, today announced that it has entered into an exclusive U.S. distribution agreement with Lumos Diagnostics for FebriDx®, a rapid point-of-care (POC) test that aids in the diagnosis of bacterial acute respiratory infection and differentiation from non-bacterial etiology in approximately 10 minutes using a single drop of blood. With strong product differentiation, FDA 510(k) clearance, and an anticipated CLIA waiver application within the next three months, FebriDx® is poised to transform how clinicians diagnose and manage respiratory infection. FebriDx® will become part of PHASE Scientific's INDICAID® portfolio – a trusted brand for high-quality, accessible rapid diagnostics. The partnership marks a significant milestone in PHASE's commercial expansion in the United States, building upon a nationwide network of urgent care centers, clinics, and healthcare providers and a proven track record of distributing over 100 million INDICAID® tests. "We are thrilled to partner with Lumos, a company that shares our commitment to shaping the future of healthcare through innovation and collaboration, and support them with our scalable go-to-market strength in North America," said Dr. Ricky Chiu, Founder and CEO of PHASE Scientific. "A powerful complement to our INDICAID® respiratory portfolio, FebriDx® is a first-in-class diagnostic that perfectly aligns with our mission to bring fast, actionable diagnostics to the frontlines of care. We are confident this will unlock synergistic opportunities, further advancing our impact on antimicrobial stewardship and clinical decision-making across the U.S. As we continue to expand the INDICAID® brand, we remain dedicated to strengthening our leadership in point-of-care solutions, empowering clinicians, and improving access to high-quality healthcare." Doug Ward, CEO of Lumos Diagnostics, commented, "This distribution agreement reflects a pivotal moment in Lumos' evolution. We look forward to working with the PHASE Scientific team to ensure that FebriDx® secures adoption in the U.S. market, delivering tangible clinical and financial value to the broader healthcare system. This agreement also validates the value of the FebriDx® technology and provides a clear pathway to the U.S. market, which we expect will accelerate rapidly should we receive a grant for CLIA waiver from the FDA. Transforming Respiratory Infection Diagnosis FebriDx® fills this diagnostic gap with a rapid, point-of-care test that uses a unique combination of C-reactive protein (CRP) and Myxovirus resistance protein A (MxA) biomarkers to aid in the diagnosis of bacterial from non-bacterial respiratory infections after 10 minutes. Its lateral flow format requires only a fingerstick blood sample and has been validated in a pivotal clinical study and demonstrated good diagnostic performance that can, in turn, improve diagnostic confidence and antibiotic stewardship decisions. By enabling faster, more informed treatment decisions, FebriDx® supports more targeted care in busy patient settings – currently including urgent and emergency care. A CLIA waiver study is progressing well, with anticipated study completion and application submission expected within the next three months. This would expand access to FebriDx® across a broader range of outpatient environments, representing a market opportunity of approximately US$1.5 billion. Driving Antimicrobial Stewardship FebriDx® plays a critical role in aiding in addressing the global threat of antimicrobial resistance (AMR), which continues to strain public health systems and drive avoidable costs. By providing rapid, actionable results at the point of care, FebriDx® helps reduce unnecessary antibiotic prescribing – a key contributor to AMR – and improves clinical workflows by supporting more accurate triage and treatment. Clinical studies have demonstrated that integrating FebriDx® can lead to reduced antibiotic use, lower healthcare costs, and better patient outcomes. Its unique ability to guide appropriate prescribing makes it a valuable tool in everyday patient care. Strengthening U.S. Market Presence This agreement represents a major step in PHASE Scientific's strategy to reinforce its dual strengths in R&D innovation and commercial execution, as well as accelerate its leadership in the U.S. diagnostics market. Known for its proprietary PHASIFY™ technology and innovation pipeline in cancer and infectious disease diagnostics, PHASE Scientific is now demonstrating its scalable go-to-market strength in North America. About PHASE Scientific PHASE Scientific International Limited ("PHASE Scientific") is a fast-growing biotech company with a mission to inspire a new state of health through innovative diagnostics and healthcare solutions. With operations in the U.S., mainland China, and Hong Kong SAR, PHASE delivers novel diagnostic tools and services for cancer and infectious diseases using proprietary technologies, empowering better disease detection, diagnosis, and management. PHASE Scientific's products and services have received certifications from the U.S. Food and Drug Administration (FDA), the European Union CE, and regulatory agencies in various countries, providing over 100 million testing products and services in more than 30 countries worldwide. PHASE Scientific has recently completed a US$34 million Series A funding round, representing the largest Series A raise in Asia's diagnostic technology sector since 2019. Other supporters include Gates Foundation, and US governmental agencies National Science Foundation and National Institutes of Health. For more information, please visit About FebriDx® FebriDx® is a unique, rapid point of care test that helps clinicians differentiate between bacterial and non-bacterial acute respiratory infections through a simple fingerstick blood sample after 10 minutes. By aiding clinicians make faster, better decisions at the point-of-care, FebriDx® has the potential to improve patient outcomes, reduce unnecessary antibiotic prescriptions, and lower overall healthcare costs – all while addressing the urgent global challenge of antimicrobial resistance (AMR). About Lumos Diagnostics Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases. For more information visit Media Contact PHASE Scientificpr@ FGS GlobalPhaseSci@ View original content to download multimedia: SOURCE PHASE Scientific

SpaceX is about to give Starlink's main rival a ride to orbit
SpaceX is about to give Starlink's main rival a ride to orbit

Digital Trends

timean hour ago

  • Digital Trends

SpaceX is about to give Starlink's main rival a ride to orbit

SpaceX has been enjoying growing uptake of its internet-from-space Starlink service, but in a weird twist, the company is about to lend a hand to its main rival in the sector. A SpaceX Falcon 9 rocket is about to launch 24 satellites for Amazon's Project Kuiper program, which, like Starlink, will offer internet connectivity to individuals and businesses globally. Recommended Videos The mission is aiming to lift off from Cape Canaveral, Florida, at 1:57 a.m. ET on Wednesday. A live webcast will begin about 15 minutes before launch, which you can watch on X @SpaceX. Amazon's Project Kuiper is still in its early days, having so far deployed only 54 internet satellites in two missions, the first of which took place in April. SpaceX's Starlink, meanwhile, is much further down the road, with more than 7,000 satellites now serving more than 5 million customers globally following its first deployment in 2019. Amazon used a United Launch Alliance (ULA) Atlas V rocket for its first two Project Kuiper satellite launches. But the regulator has insisted that it must have half of its planned 3,200 satellites deployed by the end of July 2026, with the rest facing a July 2029 deadline for deployment. Failure to meet the initial milestone could risk key license permissions, though it's thought that Amazon would probably be granted additional time if needed. The tight deadline has prompted Amazon to tap the services of multiple launch providers, with not only ULA and SpaceX but also Arianespace, and Blue Origin — the company started by Amazon founder Jeff Bezos — likely to send Project Kuiper satellites to orbit over the next 12 months and beyond. The unusual collaboration means that SpaceX is actually helping to accelerate a direct competitor's progress, a move that intensifies the high-stakes race for dominance in the orbital internet sector.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store